ChemTract
ChemTract is a sole-practitioner medicinal chemistry and drug discovery consultancy serving pharmaceutical, biotech, and nonprofit organizations.
ChemTract is a micro-consultancy whose commercial engine is the discovery reputation of a single medicinal chemist, monetized through bespoke advisory engagements rather than products, headcount, or funded programs. Demand rests on trust in that record, which suits buyers seeking senior judgment on early discovery questions.
The public footprint shows no press coverage of financings, acquisitions, or operating milestones, consistent with a quiet expert practice. Evaluation therefore centers on fit with the principal, availability, and the preclinical scope of the counsel, not on scale or growth signals.
ChemTract is a sole-practitioner consultancy based in Martinsville, New Jersey, advising pharmaceutical, biotechnology, and nonprofit organizations on medicinal chemistry and early drug discovery. Its service scope centers on lead identification and lead optimization, supported by counsel on intellectual property strategy and scientific due diligence.
Engagements range from focused guidance on individual scientific questions to in-depth review of single projects and full discovery programs. The practice tailors each assignment to the client, drawing on more than three decades of pharmaceutical industry experience in small-molecule discovery.
ChemTract operates as an owner-led practice, so clients work directly with the chemist whose discovery record underpins the firm. That record includes co-invention of the antifungal caspofungin, leadership of the team behind ibrexafungerp, and contributions to rezafungin and related programs, recognized through American Chemical Society honors and an Edison Patent Award.
Beyond the laboratory record, the principal brings governance and advisory experience from roles with Kathera Bioscience, Cidara Therapeutics, the Chemists Discovering Infectious Disease group, and Lytica Therapeutics. This combination of firsthand invention history and cross-organization perspective shapes the practical counsel offered on discovery strategy.
As a single-principal practice, ChemTract has finite bandwidth, so it cannot staff parallel programs or large outsourced workstreams the way multi-scientist consultancies and contract research firms can. Availability depends on the calendar of one expert, which limits throughput during periods of concentrated client demand.
The advisory scope also stops at preclinical and pre-IND questions, offering no regulatory filing, clinical development, or commercial guidance. The public site has seen little visible refresh since early 2023, giving prospective buyers limited fresh material to evaluate current activity.
ChemTract is a sole-practitioner medicinal chemistry and drug discovery consultancy serving pharmaceutical, biotech, and nonprofit organizations.